Patidegib topical gel

Topical HH Inhibitor (Patidegib) for Gorlin Syndrome

estimated prevalence



Gorlin syndrome, Frequent basal cell carcinoma

Genetic Source

PTCH1 (patched-1, a smoothened inhibitor)

Clinical Phase

Phase 3


topical small molecule

Patidegib topical gel is designed to selectively replace and/or augment the function of Patched (Ptc), a naturally occurring hedgehog signaling pathway inhibitor, by blocking the Smoothened (Smo) protein. Acting as a tumor suppressor, patidegib is designed to allow cells to function normally and limit the overproduction of tumors found in patients with Gorlin Syndrome and High Frequency Basal Cell Carcinoma. Because oral formulations for this treatment typically have serious systemic side effects which cause many patients to discontinue treatment, patidegib is formulated as a topical gel to reduce its side effect profile due to its minimal systemic exposure. BridgeBio is currently investigating the safety and efficacy of patidegib in patients with Gorlin Syndrome in a Phase 3 clinical trial.

our science

our science icon icon

our approach icon icon

patient resources icon icon